Pernod Ricard (RI) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
8 Apr, 2026Executive summary
H1 FY26 saw a 5.9% organic net sales decline and 14.9% reported drop, mainly due to softness in the US and China, FX headwinds, and brand disposals, while other regions showed growth and operational efficiency gains.
Operational efficiency program delivered rapid cost reductions, including a 10% drop in structural costs and improved cash generation, with one-third of €1bn target savings expected by FY26.
Free cash flow improved by 9.5% to €482m, supported by normalized strategic investments and strong working capital management.
Portfolio management continued with the disposal of Imperial Blue and other non-core brands.
FY26 is a transition year with a focus on deleveraging, sustainable value growth, and innovation.
Financial highlights
Net sales: €5,253m, down 5.9% organically and 14.9% reported; Q1 down 8%, Q2 down 5%.
Profit from Recurring Operations declined 7.5% organically and 18.7% reported, mainly due to FX.
Gross margin fell 216 bps to 59.3%, impacted by tariffs, inflation, and lower fixed cost absorption.
Free cash flow reached €482m, up 9.5% year-over-year, driven by working capital improvements.
EPS down 20% to €4.04 due to lower reported profit and negative FX.
Outlook and guidance
FY26 outlook unchanged; expects stronger H2 with improving top-line trends and organic net sales growth to accelerate.
Strategic investments revised to €750m for FY26, normalizing to ≤€800m from FY27.
Cash conversion target of 80%+ to be achieved in FY26, one year ahead of plan.
Net debt/EBITDA ratio targeted below 3x by FY29.
FX expected to be a significant headwind for the full year.
Latest events from Pernod Ricard
- Q3 organic net sales rose 4.1%, but full-year sales are forecast to decline 3–4% amid FX headwinds.RI
Q3 202616 Apr 2026 - Q1 organic sales fell 7.6%, but H2 is expected to improve as key markets recover.RI
Q1 20263 Feb 2026 - Organic sales down 1%, margins up, net profit down 35%, FY25 growth expected.RI
H2 202423 Jan 2026 - Q1 sales declined 5.9% organically, with China and US driving the downturn; guidance unchanged.RI
Q1 202519 Jan 2026 - Stable sales, margin gains, and a €4.70 dividend headline a governance-focused AGM.RI
AGM 202415 Jan 2026 - Margin and cash flow improved despite sales and profit declines amid FX and China headwinds.RI
H1 20259 Jan 2026 - Resilient results, stable dividends, and all resolutions approved amid global challenges.RI
AGM 202527 Dec 2025 - Q3 FY25 organic net sales fell 3%, but FY25 outlook and €2.35 dividend were confirmed.RI
Q3 202521 Dec 2025 - Organic sales fell 3% but margin and cash flow improved; FY26 to be a transition year.RI
H2 202523 Nov 2025